Androgen activity, ischaemic heart disease and risk factors among men in NHANES III

European Journal of Clinical Investigation

Volumn 43, Issue 12, 2013, Pages 1273-1281

  Schooling, C Mary ^a  

^a CITY UNIVERSITY OF NEW YORK   (United States)

Author keywords

Androgens; Cardiovascular; Death; Ischaemic heart disease; Men; Risk factors

Indexed keywords

ANDROSTANEDIOL; GLUCURONIDE; TESTOSTERONE;

ADOLESCENT; ADULT; ALCOHOL CONSUMPTION; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHILD; CONGESTIVE HEART FAILURE; EDUCATIONAL STATUS; ETHNICITY; FOLLOW UP; HORMONE ACTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RACE; SCHOOL CHILD; SMOKING; TESTOSTERONE BLOOD LEVEL; UNITED STATES;

ANDROGENS; CARDIOVASCULAR; DEATH; ISCHAEMIC HEART DISEASE; MEN; RISK FACTORS;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; ANDROSTANE-3,17-DIOL; BIOLOGICAL MARKERS; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETIC ANGIOPATHIES; HEMOGLOBIN A, GLYCOSYLATED; HEMOGLOBINS; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PROSPECTIVE STUDIES; RISK FACTORS; STROKE; TESTOSTERONE; UNITED STATES; WAIST CIRCUMFERENCE; YOUNG ADULT;

EID: 84888069533     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12174     Document Type: Article

References (48)

1. Araujo AB, Dixon JM, Suarez EA, Murad MH, Guey LT, Wittert GA. Clinical review: endogenous testosterone and mortality in men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2011;96:3007-19.
2. Ruige JB, Mahmoud AM, De BD, Kaufman JM. Endogenous testosterone and cardiovascular disease in healthy men: a meta-analysis. Heart 2011;97:870-5.
3. Laaksonen DE, Niskanen L, Punnonen K, Nyyssonen K, Tuomainen TP, Valkonen VP et al. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 2004;27:1036-41.
4. Khaw KT, Barrett-Connor E. Endogenous sex hormones, high density lipoprotein cholesterol, and other lipoprotein fractions in men. Arterioscler Thromb 1991;11:489-94.
5. Akishita M, Fukai S, Hashimoto M, Kameyama Y, Nomura K, Nakamura T et al. Association of low testosterone with metabolic syndrome and its components in middle-aged Japanese men. Hypertens Res 2010;33:587-91.
6. Firtser S, Juonala M, Magnussen CG, Jula A, Loo BM, Marniemi J et al. Relation of total and free testosterone and sex hormone-binding globulin with cardiovascular risk factors in men aged 24-45 years. The Cardiovascular Risk in Young Finns Study. Atherosclerosis 2012;222:257-62.
7. Haffner SM, Valdez RA, Stern MP, Katz MS. Obesity, body fat distribution and sex hormones in men. Int J Obes Relat Metab Disord 1993;17:643-9.
8. Allen NE, Appleby PN, Davey GK, Key TJ. Lifestyle and nutritional determinants of bioavailable androgens and related hormones in British men. Cancer Causes Control 2002;13:353-63.
9. Derby CA, Zilber S, Brambilla D, Morales KH, McKinlay JB. Body mass index, waist circumference and waist to hip ratio and change in sex steroid hormones: the Massachusetts Male Ageing Study. Clin Endocrinol (Oxf) 2006;65:125-31.
10. Jones TH, Arver S, Behre HM, Buvat J, Meuleman E, Moncada I et al. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care 2011;34:828-37.
11. Fernandez-Balsells MM, Murad MH, Lane M, Lampropulos JF, Albuquerque F, Mullan RJ et al. Clinical review 1: adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2010;95:2560-75.
12. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367:1187-97.
13. Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012;13:983-92.
14. Labrie F, Cusan L, Gomez JL, Martel C, Berube R, Belanger P et al. Comparable amounts of sex steroids are made outside the gonads in men and women: strong lesson for hormone therapy of prostate and breast cancer. J Steroid Biochem Mol Biol 2009;113:52-6.
15. Vandenput L, Labrie F, Mellstrom D, Swanson C, Knutsson T, Peeker R et al. Serum levels of specific glucuronidated androgen metabolites predict BMD and prostate volume in elderly men. J Bone Miner Res 2007;22:220-7.
16. Miljkovic I, Cauley JA, Dressen AS, Gordon CL, Goodpaster BH, Kuller LH et al. Bioactive androgens and glucuronidated androgen metabolites are associated with subcutaneous and ectopic skeletal muscle adiposity among older black men. Metabolism 2011;60:1178-85.
17. Selvin E, Feinleib M, Zhang L, Rohrmann S, Rifai N, Nelson WG et al. Androgens and diabetes in men: results from the Third National Health and Nutrition Examination Survey (NHANES III). Diabetes Care 2007;30:234-8.
18. Vandenput L, Mellstrom D, Lorentzon M, Swanson C, Karlsson MK, Brandberg J et al. Androgens and glucuronidated androgen metabolites are associated with metabolic risk factors in men. J Clin Endocrinol Metab 2007;92:4130-7.
19. Menke A, Guallar E, Rohrmann S, Nelson WG, Rifai N, Kanarek N et al. Sex steroid hormone concentrations and risk of death in US men. Am J Epidemiol 2010;171:583-92.
20. http://www.cdc.gov/nchs/nhanes/nh3data.htm. Accessed on 20 February 2013.
21. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999;84:3666-72.
22. Sun X, Briel M, Walter SD, Guyatt GH. Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses. BMJ 2010;340:c117.
23. Andersen PK, Abildstrom SZ, Rosthoj S. Competing risks as a multi-state model. Stat Methods Med Res 2002;11:203-15.
24. Satagopan JM, Ben-Porat L, Berwick M, Robson M, Kutler D, Auerbach AD. A note on competing risks in survival data analysis. Br J Cancer 2004;91:1229-35.
25. Field AE, Colditz GA, Willett WC, Longcope C, McKinlay JB. The relation of smoking, age, relative weight, and dietary intake to serum adrenal steroids, sex hormones, and sex hormone-binding globulin in middle-aged men. J Clin Endocrinol Metab 1994;79:1310-6.
26. Suzuki R, Allen NE, Appleby PN, Key TJ, Dossus L, Tjonneland A et al. Lifestyle factors and serum androgens among 636 middle aged men from seven countries in the European Prospective Investigation into Cancer and Nutrition (EPIC). Cancer Causes Control 2009;20:811-21.
27. Shiels MS, Rohrmann S, Menke A, Selvin E, Crespo CJ, Rifai N et al. Association of cigarette smoking, alcohol consumption, and physical activity with sex steroid hormone levels in US men. Cancer Causes Control 2009;20:877-86.
28. Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur J Clin Invest 2010;40:35-53.
29. Rittmaster RS, Zwicker H, Thompson DL, Konok G, Norman RW. Androstanediol glucuronide production in human liver, prostate, and skin. Evidence for the importance of the liver in 5 alpha-reduced androgen metabolism. J Clin Endocrinol Metab 1993;76:977-82.
30. Lazo M, Hernaez R, Bonekamp S, Kamel IR, Brancati FL, Guallar E et al. Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ 2011;343:d6891.
31. The Coronary Drug Project. Findings leading to discontinuation of the 2.5-mg day estrogen group. The coronary Drug Project Research Group. JAMA 1973;226:652-7.
32. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010;95:2536-59.
33. Braun SR. Promoting "Low T": a medical Writer's perspective. JAMA Intern Med 2013;173:1458-60.
34. Schwartz LM, Woloshin S. Low "t" as in "template": how to sell disease. JAMA Intern Med 2013;173:1460-2.
35. Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey SG. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med 2008;27:1133-63.
36. Haring R, Teumer A, Volker U, Dorr M, Nauck M, Biffar R et al. Mendelian randomization suggests non-causal associations of testosterone with cardiometabolic risk factors and mortality. Andrology 2013;1:17-23.
37. Loomba-Albrecht LA, Styne DM. Effect of puberty on body composition. Curr Opin Endocrinol Diabetes Obes 2009;16:10-5.
38. Hero M, Wickman S, Hanhijarvi R, Siimes MA, Dunkel L. Pubertal upregulation of erythropoiesis in boys is determined primarily by androgen. J Pediatr 2005;146:245-52.
39. Ajayi AA, Mathur R, Halushka PV. Testosterone increases human platelet thromboxane A2 receptor density and aggregation responses. Circulation 1995;91:2742-7.
40. Weyrich AS, Rejeski WJ, Brubaker PH, Parks JS. The effects of testosterone on lipids and eicosanoids in cynomolgus monkeys. Med Sci Sports Exerc 1992;24:333-8.
41. Torres IP, El HM, Zamora-Gonzalez J, Infante O, Chavira R, Banos G. Modulation of aortic vascular reactivity by sex hormones in a male rat model of metabolic syndrome. Life Sci 2007;80:2170-80.
42. Malkin CJ, Jones RD, Jones TH, Channer KS. Effect of testosterone on ex vivo vascular reactivity in man. Clin Sci (Lond) 2006;111:265-74.
43. Toma M, McAlister FA, Coglianese EE, Vidi V, Vasaiwala S, Bakal JA et al. Testosterone supplementation in heart failure: a meta-analysis. Circ Heart Fail 2012;5:315-21.
44. Xu L, Freeman G, Cowling BJ, Schooling CM. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med 2013;11:108.
45. Hahn RG, Farahmand BY, Hallin A, Hammar N, Persson PG. Incidence of acute myocardial infarction and cause-specific mortality after transurethral treatments of prostatic hypertrophy. Urology 2000;55:236-40.
46. Lotufo PA, Chae CU, Ajani UA, Hennekens CH, Manson JE. Male pattern baldness and coronary heart disease: the Physicians' Health Study. Arch Intern Med 2000;160:165-71.
47. Parsons JK, Carter HB, Partin AW, Windham BG, Metter EJ, Ferrucci L et al. Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab 2006;91:2562-8.
48. Schooling CM, Au Yeung SL, Freeman G, Cowling BJ. The effect of statins on testosterone in men and women, a systematic review and meta-analysis of randomized controlled trials. BMC Med 2013;11:57.